Enantiomeric composition analysis of pranoprofen in equine plasma and urine by chiral liquid chromatography-tandem mass spectrometry in selected reaction monitoring mode

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 31, 2010, Pages 3249-3254

  Yu, J ^a,b   Han, K S ^a   Lee, G ^c,d   Paik, M J ^d   Kim, K R ^b  

^a Equine Hospital   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Ajou University School of Medicine   (South Korea)

^d Ajou University   (South Korea)

Author keywords

Chiral liquid chromatography tandem mass spectrometry in selected reaction monitoring mode; Enantiomeric composition; Equine plasma and urine; Horse doping; Pranoprofen

Indexed keywords

ENANTIOMERIC COMPOSITION; EQUINE PLASMA AND URINE; HORSE DOPING; PRANOPROFEN; SELECTED REACTION MONITORING;

BODY FLUIDS; CHROMATOGRAPHY; ENANTIOMERS; LIQUIDS; MASS SPECTROMETRY; PLASMAS;

HIGH PRESSURE LIQUID CHROMATOGRAPHY;

MEFENAMIC ACID; PRANOPROFEN;

ARTICLE; BIOLOGICAL MONITORING; CHIRAL CHROMATOGRAPHY; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STRUCTURE; DRUG URINE LEVEL; ENANTIOMER; FALSE POSITIVE RESULT; HORSE; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANIMALS; BENZOPYRANS; CHROMATOGRAPHY, LIQUID; DOPING IN SPORTS; FEMALE; HORSES; MEFENAMIC ACID; PROPIONIC ACIDS; REPRODUCIBILITY OF RESULTS; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

EQUIDAE;

EID: 78449283597     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.10.002     Document Type: Article

References (24)

1. Jones W.E. J. Equine Vet. Sci. 1992, 12:265.
2. Delbeke F.T., Landuyt J., Debackere M. J. Pharmaceut. Biomed. Anal. 1995, 13:1041.
3. Landoni M.F., Lees P. J. Vet. Pharmacol. Therap. 1996, 19:466.
4. Lees P., May S.A., Hoeijmakers M., Coert A., Rens P.V. J. Vet. Pharmacol. Therap. 1999, 22:96.
5. Verde C.R., Simpson M.I., Frigoli A., Landoni M.F. J. Vet. Pharmacol. Therap. 2001, 24:179.
6. Lees P., Aliabadi F.S., Landoni M.F. J. Vet. Pharmacol. Therap. 2002, 25:433.
7. Soracel A.L., Tapia O., Garcia J. J. Vet. Pharmacol. Therap. 2005, 28:65.
8. Maurer H.H. J. Chromatogr. B 1999, 733:3.
9. Tsitsimpikou C., Spyridaki M-H.E., Georgoulakis I., Kouretas D., Konstantinidou M., Georgakopoulos C.G. Talanta 2001, 55:1173.
10. Takeda A., Tanaka H., Shinohara T., Ohtake I. J. Chromatogr. B 2001, 758:235.
11. Dumasia M.C., Ginn A., Hyde W., Peterson J., Houghton E. J. Chromatogr. B 2003, 788:297.
12. Yu N.H., Ho E.N.M., Tang F.P.W., Wan T.S.M., Wong A.S.Y. J. Chromatogr. A 2008, 1189:426.
13. Nicolas-Frey H. Annual Report on Prohibited Substances by FNCF, France 2008, Racing Medication & Testing Consortium, USA, p. 5.
14. Landoni M.F., Soraci A. Curr. Drug Metab. 2001, 2:37.
15. Lees P., Landoni M.F., Giraudel J., Toutain P.L. J. Vet. Pharmacol. Therap. 2004, 27:479.
16. Yu J., Lee G., Jeong Y., Ahn Y.H., Hu M.B., Kim S.J., Kim K.R., Paik M.J. Chromatographia 2009, 69:59.
17. Soraci A., Jaussaud P., Benoit E., Delatour P. Vet. Res. 1996, 27:13.
18. Akyol-Salman I., Leçe-Sertöz D., Baykal O. J. Ocular Pharmacol. Therap. 2007, 23:280.
19. Arima N., Kato Y. J. Pharmacobiodyn. 1990, 13:719.
20. Arima N. J. Pharmacobiodyn. 1990, 13:733.
21. Nomura T., Imai T., Otagiri M. Biol. Pharm. Bull. 1993, 16:298.
22. Imai T., Nomura N., Otagiri M. Chirality 2003, 15:318.
23. Imai T., Nomura T., Aso T.M., Otagiri M. Chirality 2003, 15:312.
24. WinNonlin™ Users Guide Ver. 3.0 1998-1999, Pharsight Corp., Mountain View, CA, USA.